Search

Search Results

1. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer

   Background

   Evaluation of human epidermal growth factor receptor 2 (HER2) overexpression caused by erb-b2 receptor tyrosine kinase 2 ( ERBB2 )...

   Hiroshi Ichikawa, Kenji Usui, ... Toshifumi Wakai in BMC Cancer

   Article Open access 11 June 2024
   

2. Transdifferentiation of cervical squamous cell carcinoma with ERBB2 amplification to adenocarcinoma: whole genome sequence analysis and successful control by anti-HER2 therapy

   Cancer cells sometimes transdifferentiate into different histological type(s) and tumors with multiple histological types can share a common ancestor...

   Hiroaki Ikushima, Kiyoshi Yamaguchi, ... Keita Uchino in BJC Reports

   Article Open access 04 September 2023
   

3. Carbonic anhydrases reduce the acidity of the tumor microenvironment, promote immune infiltration, decelerate tumor growth, and improve survival in ErbB2/HER2-enriched breast cancer

   Background

   Carbonic anhydrases catalyze CO ₂ /HCO ₃ ^– buffer reactions with implications for effective H ⁺ mobility, pH dynamics, and cellular acid–base...

   Soojung Lee, Nicolai J. Toft, ... Ebbe Boedtkjer in Breast Cancer Research

   Article Open access 25 April 2023
   

4. Circular RNA circ-ERBB2 promotes HER2-positive breast cancer progression and metastasis via sponging miR-136-5p and miR-198

   Background

   Circular RNAs (circRNAs) are pivotal regulators of various human cancers and circ-ERBB2 is abnormally expressed in breast cancer cells....

   **-xiu Zhong, Yun-yuan Kong, ... Yan-xing Guan in Journal of Translational Medicine

   Article Open access 03 November 2021
   

5. Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab

   HER2/ERBB2 evaluation is necessary for treatment decision-making in breast cancer (BC), however current methods have limitations and considerable...

   Pei Meng, Hina Dalal, ... Lao H. Saal in npj Breast Cancer

   Article Open access 19 February 2024
   

6. Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer

   Background

   Overexpression of human epidermal growth factor receptor 2 (HER2) caused by HER2 gene amplification is a driver in breast cancer...

   Caroline Rönnlund, Emmanouil G. Sifakis, ... Johan Hartman in Breast Cancer Research

   Article Open access 07 February 2024
   

7. Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer

   Background

   In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact characteristics...

   Noortje Verschoor, Marcel Smid, ... John W. M. Martens in Breast Cancer Research

   Article Open access 15 November 2023
   

8. Brustkrebs

   Brustkrebs (Mammakarzinom) ist eine der Haupttodesursachen bei Frauen, vergleichbar mit Lungen- und Darmkrebs. Ein Thema in diesem Kapitel sind die...

   Wolfgang A. Schulz in Molekularbiologie menschlicher Krebserkrankungen

   Chapter 2024
   

9. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

   The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain...

   Fernanda Mosele, Elise Deluche, ... Fabrice André in Nature Medicine

   Article Open access 24 July 2023
   

10. Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas

    Background

    The “HER2-low” nomenclature identifies breast carcinomas (BCs) displaying a HER2 score of 1+/2+ in immunohistochemistry and lacking ERBB2 ...

    Enrico Berrino, Laura Annaratone, ... Caterina Marchiò in Genome Medicine

    Article Open access 29 August 2022
    

11. HER2-targeted therapies in cancer: a systematic review

    Abnormal alterations in human epidermal growth factor receptor 2 (HER2, neu, and erbB2) are associated with the development of many tumors. It is...

    Kunrui Zhu, **nyi Yang, ... Hong Zheng in Biomarker Research

    Article Open access 02 February 2024
    

12. Breast Cancer

    Breast cancers are a major cause of mortality in females, on a par with lung and colon cancers. One topic in this chapter are the causes of breast...

    Wolfgang A. Schulz in Molecular Biology of Human Cancers

    Chapter 2023
    

13. NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

    Background

    We previously reported our phase Ib trial, testing the safety, tolerability, and efficacy of T-DM1 + neratinib in HER2-positive metastatic...

    Samuel A. Jacobs, Ying Wang, ... Katherine L. Pogue-Geile in Breast Cancer Research

    Article Open access 22 April 2024
    

14. Perturbation and stability of PAM50 subty** in population-based primary invasive breast cancer

    PAM50 gene expression subtypes represent a cornerstone in the molecular classification of breast cancer and are included in risk prediction models to...

    Srinivas Veerla, Lennart Hohmann, ... Johan Staaf in npj Breast Cancer

    Article Open access 19 October 2023
    

15. Genetic and clinical landscape of ER + /PR- breast cancer in China

    Background

    Estrogen receptor-positive and progesterone receptor-negative (ER + /PR-) breast cancer comprise a special type. More than 10% breast...

    Danian Dai, Hongmei Wu, ... Bo Chen in BMC Cancer

    Article Open access 04 December 2023
    

16. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

    Trastuzumab deruxtecan (T-DXd) showed statistically significant clinical improvement in patients with human epidermal growth factor receptor...

    Kohei Shitara, Yung-Jue Bang, ... Kensei Yamaguchi in Nature Medicine

    Article Open access 14 May 2024
    

17. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis

    Background

    Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for about 20% of all breast cancer cases and is correlated...

    Jiahui Nie, Suying Dang, ... Wei Zhang in Breast Cancer Research

    Article Open access 29 January 2024
    

18. Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis

    Background

    Tumor heterogeneity has frequently been observed in gastric cancer (GC), but the correlation between patients’ clinico-pathologic features...

    Gen Tsujio, Koji Maruo, ... Masakazu Yashiro in BMC Cancer

    Article Open access 01 June 2022
    

19. Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes

    Background

    We aimed to identify the relationship between the genomic characteristics and clinical outcomes of oligo-metastatic breast cancer.

    ...

    Kuikui Jiang, Danyang Zhou, ... Shusen Wang in BMC Cancer

    Article Open access 15 September 2023
    

20. Integrated approach to functional analysis of an ERBB2 variant of unknown significance detected by a cancer gene panel test

    Purpose

    Dealing with variants of unknown significance (VUS) is an important issue in the clinical application of NGS-based cancer gene panel tests. We...

    Yohei Harada, Akemi Sato, ... Naoko Sueoka-Aragane in Cellular Oncology

    Article Open access 08 January 2022